Bank of New York Mellon’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Bank of New York Mellon’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-51,237	Closed	-$98K	–	4488
2015 Q3	$98K	Buy	+51,237	New	+$135K	﹤0.01%	4119
2014 Q2	–	Sell	-3,508	Closed	-$76K	–	4346
2014 Q1	$76K	Buy	3,508 +550	+19%	+$15.9K	﹤0.01%	4035
2013 Q4	$104K	Buy	2,958 +215	+8%	+$7.21K	﹤0.01%	4008
2013 Q3	$99K	Sell	2,743 -14	-0.5%	-$638	﹤0.01%	3962
2013 Q2	$125K	Buy	+2,757	New	+$125K	﹤0.01%	3884

Other funds holding KBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Bank of New York Mellon's KBIO Position: Q4 2015 in Review

Bank of New York Mellon sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2015, closing a stake of 51,237 shares — an estimated $98K sold.

Bank of New York Mellon first reported a position in KBIO in Q2 2013 and held it in 5 quarters. The position peaked at $125K in Q2 2013. 17 funds tracked by Wall St. Rank hold KBIO as of Q4 2015.

Bank of New York Mellon reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2015 after selling out during the quarter.
Bank of New York Mellon sold 51,237 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2015, an estimated $98K.
Bank of New York Mellon first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 5 quarters.
Bank of New York Mellon's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $125K in Q2 2013.
17 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2015.

Based on Bank of New York Mellon's 13F filing for Q4 2015, filed 12 Feb 2016.